Zobrazeno 1 - 10
of 19
pro vyhledávání: '"James D Mellor"'
Publikováno v:
Case Reports in Oncological Medicine, Vol 2012 (2012)
A 77-year-old female with recurrent non-small-cell lung cancer presented to a hospital outpatient clinic with tremor, weakness, inability to coordinate motor movements, and confusion. It was suspected that the symptoms were due to possible central ne
Externí odkaz:
https://doaj.org/article/fc9148bfeb8747d8b9c4470dd8c4923f
Autor:
Mary Duffy, Clare Walter, James D Mellor, Linda Mileshkin, Sue Kirsa, Alan Herschtal, Carol A Rice, David Ball
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 12:e367-e374
AimMedication misadventure contributes to unplanned hospital admissions. General practitioners (GPs) may lack experience in managing problems involving complex cancer-related medication. A previous survey explored the unmet needs of lung cancer outpa
Publikováno v:
Medical Journal of Australia. 201:49-53
Objectives To evaluate the efficacy and tolerability of ipilimumab in an Australian clinical setting, and to assess the association of response with melanoma subtype, BRAF mutation status, absolute lymphocyte count and incidence of serious immune-rel
Publikováno v:
Journal of Oncology Pharmacy Practice. 20:225-228
A 54-year-old male with relapsed primary cerebral lymphoma and normal renal function was treated with methotrexate (MTX) 3 g/m2 monthly by intravenous infusion. Throughout treatment the patient self-administered a complementary medicine (Jason Winter
Publikováno v:
Internal Medicine Journal. 42:1224-1229
BACKGROUND: The off-label use of a drug refers to a use outside the terms of its approval by the Therapeutic Goods Administration (TGA). It is also possible to prescribe unlicensed drugs under the TGA's special access scheme. A high rate of off-label
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 9:169-175
Aim To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 8:319-324
Currently multiple antithrombotic agents are used for thalidomide thromboprophylaxis in multiple myeloma patients. Agents used include low-dose aspirin, fixed low-dose and therapeutic warfarin and prophylactic low molecular weight heparin. To evaluat
Publikováno v:
Supportive Care in Cancer. 20:2531-2535
Carmustine is a nitrosurea alkylating agent predominantly used at Peter MacCallum Cancer Centre as part of the autologous stem cell transplant induction regimens Stanford BCNU and BEAM. Acute infusion reactions were anecdotally reported to be higher
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 7:106-113
The use of targeted anti-cancer agents is increasing. It is common to utilize a multi-modal treatment approach towards solid tumors, often including surgical resection, and it has become apparent that some targeted agents can impair wound healing or
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 5:242-246
Aim: Oncology is an area with a high prevalence of off-label and unlicensed prescribing. A previous audit conducted in 2001 at the Peter MacCallum Cancer Centre, a specialist oncology hospital, showed that 22% of all prescriptions were either off-lab